Literature DB >> 25772897

Pathological mechanisms in progressive multiple sclerosis.

Don H Mahad1, Bruce D Trapp2, Hans Lassmann3.   

Abstract

A better understanding of the pathological mechanisms that drive neurodegeneration in individuals with multiple sclerosis is needed to develop therapies that will effectively treat patients in the primary and secondary progressive stages of the disease. We propose that the inflammatory demyelinating disease process in early multiple sclerosis triggers a cascade of events that lead to neurodegeneration and are amplified by pathogenic mechanisms related to brain ageing and accumulated disease burden. Key elements driving neurodegeneration include microglia activation, chronic oxidative injury, accumulation of mitochondrial damage in axons, and age-related iron accumulation in the human brain. Altered mitochondrial function in axons might be of particular importance. This process leads to chronic cell stress and imbalance of ionic homoeostasis, resulting in axonal and neuronal death. The evidence suggests that treatment of progressive multiple sclerosis should be based on a combination of anti-inflammatory, regenerative, and neuroprotective strategies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772897     DOI: 10.1016/S1474-4422(14)70256-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  322 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 2.  Role of long non-coding RNAs (LncRNAs) in multiple sclerosis: a brief review.

Authors:  Eskandar Taghizadeh; Forough Taheri; Mohammad Mahdi Samadian; Mohammad Soudyab; Abbas Abi; Seyed Mohammad Gheibi Hayat
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

3.  Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.

Authors:  G Pontillo; S Cocozza; R Lanzillo; C Russo; M D Stasi; C Paolella; E A Vola; C Criscuolo; P Borrelli; G Palma; E Tedeschi; V B Morra; A Elefante; A Brunetti
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-20       Impact factor: 3.825

Review 4.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

5.  Chronic demyelination-induced seizures.

Authors:  Andrew S Lapato; Jenny I Szu; Jonathan P C Hasselmann; Anna J Khalaj; Devin K Binder; Seema K Tiwari-Woodruff
Journal:  Neuroscience       Date:  2017-01-30       Impact factor: 3.590

Review 6.  Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation.

Authors:  Anastasia I Petra; Smaro Panagiotidou; Erifili Hatziagelaki; Julia M Stewart; Pio Conti; Theoharis C Theoharides
Journal:  Clin Ther       Date:  2015-05-01       Impact factor: 3.393

7.  Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.

Authors:  Chunling Liu; Hui Liu; Hongjun Jin; Xuyi Yue; Zonghua Luo; Zhude Tu
Journal:  J Neuroimmunol       Date:  2018-02-12       Impact factor: 3.478

8.  Motor reaction time and accuracy in patients with multiple sclerosis: effects of an active computerized training program.

Authors:  Amir Dana; Saleh Rafiee; Amin Gholami
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307

Review 9.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.